Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29434809 | 1.00 | HTT (0.46) | HTTNPSR1 | |
| SCHEMBL4930349 | 0.94 | HTT (0.41) | HTTNPSR1 | |
| SCHEMBL4925854 | 0.93 | PDE7A (0.41) | — | |
| SCHEMBL4928736 | 0.91 | HTT (0.46) | HTTNPSR1 | |
| SCHEMBL2520513 | 0.91 | HTT (0.45) | HTTNPSR1 | |
| SCHEMBL4930490 | 0.89 | HTT (0.53) | HTTNPSR1 | |
| SCHEMBL4924964 | 0.89 | KMT2A (0.52) | HTTNPSR1 | |
| SCHEMBL4931851 | 0.88 | KMT2A (0.50) | — | |
| SCHEMBL4933920 | 0.88 | PDE7A (0.45) | — | |
| SCHEMBL4921507 | 0.88 | NPC1 (0.46) | HTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715637-B | Glucokinase activators and methods of use thereof | 百时美施贵宝公司 | 2022-04-05 | — | — | CN | disclosed |
| US-10604541-B2 | Glucokinase activators and methods of using same | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-01 | — | — | US | disclosed |
| EP-2850073-B1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2017-07-19 | — | — | EP | disclosed |
| US-9174965-B2 | Pyrimidinylpiperidinyloxypyridone analogues as GPR119 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2566862-B1 | BENZOFURANYL ANALOGUES AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-09-16 | — | — | EP | disclosed |
| US-9062028-B2 | Bicyclic nitrogen containing heteroaryl TGR5 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| WO-2015061272-A1 | ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-04-30 | — | — | WO | disclosed |
| EP-2556069-B1 | 4-(1-(PYRIMIDIN-2-YL)PIPERIDIN-4-YLOXY)PYRIDIN-2-ONE COMPOUNDS AS GPR119 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2015-04-01 | — | — | EP | disclosed |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-22 | — | — | US | disclosed |
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2009-01-15 | — | — | US | disclosed |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2008-11-27 | — | — | US | disclosed |
| WO-2008137435-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| US-20080021069-A1 | Receptor Function Regulating Agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
| EP-1810677-A1 | RECEPTOR FUNCTION REGULATING AGENT | Takeda Pharmaceutical Company Limited (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018055-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR139, GPR4 | HTT 3195/4885NPSR1 118/4885 |
| US-10604541-B2 | Glucokinase activators and methods of using same | GCK, GCKR, GALK1 | HTT 1970/4885NPSR1 3416/4885 |
| US-20150133479-A1 | PYRIMIDINYLPIPERIDINYLOXYPYRIDONE ANALOGUES AS GPR119 MODULATORS | GPR119, GPR180, GPR139 | HTT 2119/4885NPSR1 192/4885 |
| US-20080021069-A1 | Receptor Function Regulating Agent | GPR119, INSR, GPR65 | HTT 4035/4885NPSR1 103/4885 |
| US-20080293690-A1 | [6,6] AND [6,7]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR6, GPR139 | HTT 3138/4885NPSR1 132/4885 |
| US-20190233449-A1 | GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME | GCK, GCKR, GALK1 | HTT 1970/4885NPSR1 3416/4885 |
| US-20090023702-A1 | PYRIDONE GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | GPR119, GPR65, GPR27 | HTT 3925/4885NPSR1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.